Call for Papers  

Article Details

Review Article

Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment


Chenchen Ma, Siyuan Cui and Ruirong Xu*   Pages 1 - 30 ( 30 )


Background: FMS-like tyrosine kinase 3 (FLT3) is a commonly mutated gene in acute myeloid leukemia. As a receptor tyrosine kinase (RTK), FLT3 plays a role in the proliferation and differentiation of hematopoietic stem cells. As the most frequent molecular alteration in AML, FLT3 has drawn the attention of many researchers, and a lot of small molecule inhibitors targeting FLT3 have been intensively investigated as potential drugs for AML therapy.

Methods: In this paper, PubMed and SciFinder® were used as a tool; the publications about “FLT3 inhibitor” and “Acute myeloid leukemia” were surveyed from 2014 to the present with an exclusion of those published as patents.

Results: In this study, the structural characterization and biological activities of representative FLT3 inhibitors were summarized. The major challenges and future directions for further research are discussed.

Conclusion: Recently, numerous FLT3 inhibitors have been discovered and employed in FLT3-mutated AML treatment. In order to overcome the drug resistance caused by FLT3 mutations, screening multitargets FLT3 inhibitors has become the main research direction. In addition, the emergence of irreversible FLT3 inhibitors also provides new ideas for discovering new FLT3 inhibitors.


AML,FLT3,FLT3 Inhibitors,Anticancer activity,Structure Modification,SARs


Read Full-Text article